Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 08 December 2024

Created: 08 December 2024

Last Updated: 08 December 2024

52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of response and median PFS not yet reached

Posted: 2024-12-08 17:00:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) - Newscast

Why Cogent Biosciences Inc (COGT) Stock is Currently 2.18% Above from Its 20-Day SMA?

Sat, 18 Jan 2025 10:00:00 GMT Cogent Biosciences Inc (COGT) stock saw a decline, ending the day at $8.03 which represents a decrease of $-0.10 or -1.23% from the prior close of $8.13. The stock opened at $8.24 and touched a low of ...

Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Price Target at $14.83

Thu, 16 Jan 2025 22:15:00 GMT Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, ...

Why Did Cogent Biosciences Inc (COGT) Stock Plunge -1.58% Last Week?

Thu, 16 Jan 2025 11:20:00 GMT Cogent Biosciences Inc (COGT) stock saw a modest uptick, ending the day at $8.12 which represents a slight increase of $0.75 or 10.18% from the prior close of $7.37. The stock opened at $8 and touched ...

Cogent and ModivCare gain after insider purchases

Wed, 15 Jan 2025 11:49:19 GMT Cogent Biosciences (COGT) stock, ModivCare (MODV) stock, and Avadel Pharmaceuticals (AVDL) stock rise after insider purchases. Read more here.

Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Mon, 13 Jan 2025 05:25:00 GMT Report top-line results during the second half of 2025 from the APEX trial. APEX is a registration-directed, global, open-label trial of bezuclastinib in patients with Advanced Systemic Mastocytosis ...